Literature DB >> 31664865

Improving Pulmonary Immunity to Bacterial Pathogens through Streptococcus pneumoniae Colonization of the Nasopharynx.

Jeremy S Brown1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 31664865      PMCID: PMC6999096          DOI: 10.1164/rccm.201910-2047ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
Streptococcus pneumoniae is a common cause of bacterial pneumonia, especially in the elderly and patients with significant comorbidities, and is also frequently associated with exacerbations of chronic obstructive pulmonary disease (1, 2). Existing S. pneumoniae vaccines have partial strain coverage, may lack efficacy in high-risk groups, and generally seem to have poorer efficacy against pulmonary infection than against systemic infection (3, 4). Hence, alternative strategies to conventional vaccines may be required to prevent the persistent high morbidity and mortality caused by S. pneumoniae lung infections. Mitsi and colleagues present data obtained using the experimental human pneumococcal colonization (EHPC) model that suggest one such alternative strategy for preventing pneumonia caused by multiple bacterial pathogens, including S. pneumoniae. Repeated episodes of S. pneumoniae colonization throughout life induce and repeatedly boost protective antibody to both capsular and multiple protein antigens, as well as poorly defined cellular immunity (5–8). In a study presented in this issue of the Journal, Mitsi and colleagues (pp. 335–347) used the EHPC model to investigate the effects of S. pneumoniae colonization on alveolar macrophage (AM) function in healthy volunteers and identified a novel mechanism by which successful colonization improves lung immunity to multiple bacterial pathogens (9). The phagocytic capacity of S. pneumoniae AMs (recovered by BAL) improved from 69% in uncolonized EHPC subjects to 80.4% in EHPC subjects who were successfully colonized. This was a convincing change that was strengthened by a significant correlation to the density of S. pneumoniae colonization of the nasopharynx. Matched pre- and postcolonization data from each subject would clearly provide stronger evidence that successful S. pneumoniae nasopharyngeal colonization was responsible for the differences in AM phenotypes; however, obtaining such data would be logistically difficult because it would require each volunteer to undergo two bronchoscopies, and the first bronchoscopy could also affect the function of AMs recovered by the second bronchoscopy. AM phagocytosis of invading pathogens is a major component of pulmonary innate immunity (10–12). However, whether a 16% relative increase in AM phagocytic capacity translates into improved protection against pneumonia is not at all clear—we simply do not know what degree of improvement in AM phagocytosis in vitro will result in a reduced risk of pneumonia. Furthermore, bacteria were opsonized with 1/16 pooled human IgG as well as complement, and these conditions may not accurately represent the situation in epithelial lining fluid. Under alternative opsonizing conditions, the strength of the difference between AMs obtained from colonized and uncolonized individuals may vary. However, whether bacteria that reach the lung establish active infection depends on a balance between host clearance mechanisms (i.e., mucociliary clearance and epithelial cell– and AM-mediated killing mechanisms) and pathogen virulence (a combination of replication rate and efficacy in evading pulmonary immunity) (Figure 1) (10). It is therefore feasible that even a 16% relative improvement in AM phagocytosis could tip the balance in favor of the host in a substantial proportion of bacterial invasion events, and importantly, the duration of this effect was surprisingly long (up to 120 days). However, it will require carefully designed animal experiments and eventually clinical trials to demonstrate whether this improvement in AM function translates to improved protection against infection. In addition to their role as phagocytes, AMs act as sentinel cells that initiate inflammation (11), and it will be important to assess whether the macrophage inflammatory response to bacterial pathogens is affected by prior S. pneumoniae colonization, as this may also alter susceptibility to pneumonia.
Figure 1.

Mechanisms by which nasopharyngeal colonization by Streptococcus pneumoniae may improve protection against pneumonia. Colonization boosts preexisting cellular (protein antigen–dependent T-helper cell type 1 [Th1], Th2, and Th17 CD4) and humoral (antibody to both protein and capsular antigens) adaptive immunity to S. pneumoniae (A) (5–8). Mitsi and colleagues (9) show that colonization leads to improved alveolar macrophage (AM) phagocytic capacity (B), potentially mediated by Th1 cellular immune responses (C) or by an antigen-independent trained immunity response (D). In addition, improved antibody responses could increase AM phagocytic capacity by improving S. pneumoniae opsonization (E). Improved phagocytic capacity increases the clearance of bacterial pathogens that reach the lung, potentially shifting the outcome of early bacterial/host interactions toward prevention of pneumonia (F). Mitsi and colleagues also show S. pneumoniae persistence within the lungs, which could contribute to improved immune responses (G) or could be a source of bacteria that develop into active infection (H) if bacterial numbers are poorly controlled. COPD = chronic obstructive pulmonary disease.

Mechanisms by which nasopharyngeal colonization by Streptococcus pneumoniae may improve protection against pneumonia. Colonization boosts preexisting cellular (protein antigen–dependent T-helper cell type 1 [Th1], Th2, and Th17 CD4) and humoral (antibody to both protein and capsular antigens) adaptive immunity to S. pneumoniae (A) (5–8). Mitsi and colleagues (9) show that colonization leads to improved alveolar macrophage (AM) phagocytic capacity (B), potentially mediated by Th1 cellular immune responses (C) or by an antigen-independent trained immunity response (D). In addition, improved antibody responses could increase AM phagocytic capacity by improving S. pneumoniae opsonization (E). Improved phagocytic capacity increases the clearance of bacterial pathogens that reach the lung, potentially shifting the outcome of early bacterial/host interactions toward prevention of pneumonia (F). Mitsi and colleagues also show S. pneumoniae persistence within the lungs, which could contribute to improved immune responses (G) or could be a source of bacteria that develop into active infection (H) if bacterial numbers are poorly controlled. COPD = chronic obstructive pulmonary disease. Another novel observation made by Mitsi and colleagues was the detection of S. pneumoniae in BAL by PCR and culture in 41% of successfully colonized subjects, at a time when they had already been treated with amoxicillin and had no detectable nasopharyngeal colonization with S. pneumoniae. Previously it was believed that S. pneumoniae that reached the lungs by microaspiration from the nasopharynx were rapidly cleared or occasionally resulted in pneumonia. These data show that S. pneumoniae can persist within the lung even after colonization has been cleared, creating a reservoir of bacteria that could cause ongoing immune stimulation or even develop into pneumonia at a later stage. S. pneumoniae could persist in the lung due to colonization of the bronchial tree, becoming part of the respiratory microbiome; however, it is also possible that they survive within AMs in a manner similar to that observed for Mycobacterium tuberculosis. S. pneumoniae is classically considered a purely extracellular pathogen, yet recent data suggest that this view is too simplistic. Some S. pneumoniae can persist within macrophages for many hours (12), and S. pneumoniae have even been shown to replicate within a specific subset of marginal zone splenic macrophages (13). Intriguingly, Mitsi and colleagues identified S. pneumoniae internalized by AMs, an observation that needs further investigation to characterize which cellular compartment contains the bacteria, the viability of the bacteria, and whether a particular subtype of AMs is involved. What is the mechanism for improved AM phagocytic capacity after successful S. pneumoniae nasopharyngeal colonization? The authors suggest two plausible mechanisms: 1) trained immunity, with exposure to S. pneumoniae stimulating epigenetic changes in AMs, and 2) release of IFN-γ from antigen-stimulated T-helper cell type 1 (Th1) CD4 cells, resulting in improved AM function. A Th1 mechanism is supported by the association of successful colonization with increased numbers of BAL Th1 CD4 cells, and by the positive correlation between AM phagocytic function and IFN-γ expression by lung CD4 cells after restimulation with S. pneumoniae. In addition, NanoString PCR showed that colonization was associated with a shift in the AM phenotype toward a Th1-activated pattern, and this also showed some correlation with improved phagocytosis. It is important to clarify which mechanism(s) is involved because this may identify how the findings by Mitsi and colleagues can be exploited to prevent lung infections. Possible strategies include nasal administration of live virulence-attenuated S. pneumoniae, S. pneumoniae Th1 antigens, and bacterial components that stimulate trained immunity in AMs. The data presented by Mitsi and colleagues both challenge our preconceptions about S. pneumoniae biology and describe a novel mechanism that may improve lung immunity to bacterial pathogens. The results show that the interactions between bacterial colonization of the respiratory tract and host immunity are highly complex, and further investigation of these interactions could lead to novel strategies for preventing bacterial lung infections.
  12 in total

Review 1.  Alveolar macrophage in the driver's seat.

Authors:  Bart N Lambrecht
Journal:  Immunity       Date:  2006-04       Impact factor: 31.745

2.  Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Authors:  Seema Jain; Wesley H Self; Richard G Wunderink; Sherene Fakhran; Robert Balk; Anna M Bramley; Carrie Reed; Carlos G Grijalva; Evan J Anderson; D Mark Courtney; James D Chappell; Chao Qi; Eric M Hart; Frank Carroll; Christopher Trabue; Helen K Donnelly; Derek J Williams; Yuwei Zhu; Sandra R Arnold; Krow Ampofo; Grant W Waterer; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Jonathan A McCullers; Andrew T Pavia; Kathryn M Edwards; Lyn Finelli
Journal:  N Engl J Med       Date:  2015-07-14       Impact factor: 91.245

3.  Nasal Pneumococcal Density Is Associated with Microaspiration and Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens.

Authors:  Elena Mitsi; Beatriz Carniel; Jesús Reiné; Jamie Rylance; Seher Zaidi; Alessandra Soares-Schanoski; Victoria Connor; Andrea M Collins; Andreas Schlitzer; Elissavet Nikolaou; Carla Solórzano; Sherin Pojar; Helen Hill; Angela D Hyder-Wright; Kondwani C Jambo; Marco R Oggioni; Megan De Ste Croix; Stephen B Gordon; Simon P Jochems; Daniela M Ferreira
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

4.  Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD.

Authors:  Davinder S Garcha; Sarah J Thurston; Anant R C Patel; Alexander J Mackay; James J P Goldring; Gavin C Donaldson; Timothy D McHugh; Jadwiga A Wedzicha
Journal:  Thorax       Date:  2012-08-03       Impact factor: 9.139

5.  Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses.

Authors:  R Wilson; J M Cohen; R J Jose; C de Vogel; H Baxendale; J S Brown
Journal:  Mucosal Immunol       Date:  2014-10-29       Impact factor: 7.313

6.  Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study.

Authors:  P Turner; C Turner; N Green; L Ashton; E Lwe; A Jankhot; N P Day; N J White; F Nosten; D Goldblatt
Journal:  Clin Microbiol Infect       Date:  2013-12       Impact factor: 8.067

7.  Naturally Acquired Human Immunity to Pneumococcus Is Dependent on Antibody to Protein Antigens.

Authors:  Robert Wilson; Jonathan M Cohen; Mark Reglinski; Ricardo J Jose; Win Yan Chan; Helina Marshall; Corné de Vogel; Stephen Gordon; David Goldblatt; Fernanda C Petersen; Helen Baxendale; Jeremy S Brown
Journal:  PLoS Pathog       Date:  2017-01-30       Impact factor: 6.823

8.  A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13.

Authors:  Brendan W Wren; Jeremy S Brown; Mark Reglinski; Giuseppe Ercoli; Charlie Plumptre; Emily Kay; Fernanda C Petersen; James C Paton
Journal:  NPJ Vaccines       Date:  2018-10-31       Impact factor: 7.344

9.  Alveolar Macrophage Apoptosis-associated Bacterial Killing Helps Prevent Murine Pneumonia.

Authors:  Julie A Preston; Martin A Bewley; Helen M Marriott; A McGarry Houghton; Mohammed Mohasin; Jamil Jubrail; Lucy Morris; Yvonne L Stephenson; Simon Cross; David R Greaves; Ruth W Craig; Nico van Rooijen; Colin D Bingle; Robert C Read; Timothy J Mitchell; Moira K B Whyte; Steven D Shapiro; David H Dockrell
Journal:  Am J Respir Crit Care Med       Date:  2019-07-01       Impact factor: 21.405

10.  Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults.

Authors:  Daniela M Ferreira; Daniel R Neill; Mathieu Bangert; Jenna F Gritzfeld; Nicola Green; Adam K A Wright; Shaun H Pennington; Laura Bricio-Moreno; Laura Bricio Moreno; Adriana T Moreno; Eliane N Miyaji; Angela D Wright; Andrea M Collins; David Goldblatt; Aras Kadioglu; Stephen B Gordon
Journal:  Am J Respir Crit Care Med       Date:  2013-04-15       Impact factor: 21.405

View more
  1 in total

1.  Protective Effect of Nasal Colonisation with ∆cps/piaA and ∆cps/proABCStreptococcus pneumoniae Strains against Recolonisation and Invasive Infection.

Authors:  Elisa Ramos-Sevillano; Giuseppe Ercoli; José Afonso Guerra-Assunção; Philip Felgner; Rafael Ramiro de Assis; Rie Nakajima; David Goldblatt; Kevin Kweku Adjei Tetteh; Robert Simon Heyderman; Stephen Brian Gordon; Daniela Mulari Ferreria; Jeremy Stuart Brown
Journal:  Vaccines (Basel)       Date:  2021-03-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.